vinpocetine has been researched along with Weight Gain in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, JH; Chun, KH; Kim, H; Kim, NJ; Lee, J; Song, JK | 1 |
| Abreu-Villaça, Y; Ferreira-Rosa, K; Filgueiras, CC; Kubrusly, RC; Manhães, AC; Nunes, F; Pereira, Mdos S | 1 |
| Nekrassov, V; Sitges, M | 1 |
3 other study(ies) available for vinpocetine and Weight Gain
| Article | Year |
|---|---|
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Topics: 3T3 Cells; Adipocytes; Adipogenesis; Adipokines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 1; Lipolysis; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; STAT3 Transcription Factor; Uncoupling Protein 1; Vinca Alkaloids; Weight Gain | 2019 |
Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder.
Topics: Alcohol Drinking; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Depressants; Cyclic AMP; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Ethanol; Female; Fetal Alcohol Spectrum Disorders; Humans; Male; Mice; Motor Activity; Phosphodiesterase Inhibitors; Pregnancy; Pregnancy Complications; Single-Blind Method; Survival Rate; Vinca Alkaloids; Weight Gain | 2011 |
Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Auditory Pathways; Auditory Threshold; Deafness; Evoked Potentials, Auditory, Brain Stem; Guinea Pigs; Male; Neuroprotective Agents; Reaction Time; Sodium Channel Blockers; Sodium Channels; Survival Rate; Vinca Alkaloids; Weight Gain | 2000 |